| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HKR2 |
| Uniprot No | P10073 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-491aa |
| 氨基酸序列 | MAIPKHSLSPVPWEEDSFLQVKVEEEEEASLSQGGESSHDHIAHSEAARLRFRHFRYEEASGPHEALAHLRALCCQWLQPEAHSKEQILELLVLEQFLGALPPEIQAWVGAQSPKSGEEAAVLVEDLTQVLDKRGWDPGAEPTEASCKQSDLGESEPSNVTETLMGGVSLGPAFVKACEPEGSSERSGLSGEIWTKSVTQQIHFKKTSGPYKDVPTDQRGRESGASRNSSSAWPNLTSQEKPPSEDKFDLVDAYGTEPPYTYSGKRSSKCRECRKMFQSASALEAHQKTHSRKTPYACSECGKAFSRSTHLAQHQVVHTGAKPHECKECGKAFSRVTHLTQHQRIHTGEKPYKCGECGKTFSRSTHLTQHQRVHTGERPYECDACGKAFSQSTHLTQHQRIHTGEKPYKCDACGRAFSDCSALIRHLRIHSGEKPYQCKVCPKAFAQSSSLIEHQRIHTGEKPYKCSDCGKAFSRSSALMVHLRIHITVLQ |
| 分子量 | 81 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于当前知识的关于重组人HKR2蛋白的可能研究方向及假设性文献示例(注：HKR2蛋白可能非常冷门或存在名称差异，建议进一步核实名称准确性)：
---
1. **文献名称**：*Expression and Purification of Recombinant Human HKR2 Protein for Functional Studies*
**作者**：Zhang Y, et al.
**摘要**：本研究成功在大肠杆菌系统中表达并纯化了重组人HKR2蛋白，验证了其与细胞增殖相关的功能，为后续肿瘤治疗靶点研究提供基础。
2. **文献名称**：*HKR2 as a Novel Receptor in Immune Signaling Pathways*
**作者**：Wang L, et al.
**摘要**：研究通过重组HKR2蛋白揭示了其在TLR信号通路中的调控作用，表明其可能参与炎症反应的负向调控机制。
3. **文献名称**：*Structural Characterization of HKR2 and Its Role in Metabolic Disorders*
**作者**：Smith J, et al.
**摘要**：利用重组HKR2蛋白解析了其晶体结构，发现其与胰岛素抵抗相关，可能成为代谢综合征治疗的潜在靶标。
---
**注意**：若上述示例与实际文献不符，可能是由于以下原因：
1. HKR2名称可能存在拼写错误或非标准命名(如HER2、HK2等);
2. 该蛋白研究尚处早期，公开数据有限。
**建议**：
- 核实名称准确性，尝试检索“HKR2”别名(如基因名HGNC符号)。
- 扩展搜索关键词(如“HKR2 gene function”或结合疾病名称)。
- 查阅预印本平台(如bioRxiv)或联系相关领域学者获取最新进展。
The human HER2 (human epidermal growth factor receptor 2), also known as ERBB2. is a transmembrane tyrosine kinase receptor belonging to the EGFR family. It plays a critical role in regulating cell proliferation, differentiation, and survival by forming homodimers or heterodimers with other EGFR members upon ligand binding. HER2 lacks a known ligand but is activated through dimerization, particularly via overexpression, which is observed in 15–30% of breast and gastric cancers. This overexpression drives uncontrolled signaling pathways (e.g., MAPK, PI3K/Akt), promoting tumorigenesis, metastasis, and therapy resistance.
Recombinant human HER2 protein is produced using biotechnological platforms like mammalian or bacterial expression systems, enabling large-scale purification of extracellular or intracellular domains. It serves as a vital tool for studying HER2’s structural-functional relationships, signaling mechanisms, and interactions with therapeutic agents. Researchers utilize it to develop and validate HER2-targeted therapies, including monoclonal antibodies (e.g., trastuzumab, pertuzumab) and tyrosine kinase inhibitors (e.g., lapatinib). Additionally, recombinant HER2 is employed in diagnostic assays (e.g., IHC, ELISA) to assess HER2 expression levels in clinical samples, guiding treatment decisions. Its role in generating anti-HER2 antibodies and optimizing personalized therapeutic strategies underscores its importance in advancing oncology research and precision medicine.
×
